LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Regeneron investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you ca ...